Second- or Third-degree Burns Clinical Trial
— ADSCs-BWsOfficial title:
Safety and Efficacy Evaluation of Tissue Engineered Construct Based on Allogeneic Adipose-derived Multipotent Mesenchymal Stromal Cells and Platelet-poor Plasma Fibrin Hydrogel to Treat the Patients With Burn Wounds
The purpose of this study is to evaluate safety and efficacy of tissue engineered construct based on allogeneic cultured adipose-derived multipotent mesenchymal stromal cells (ALLO-ADSCs) and platelet-poor plasma fibrin hydrogel to treat patients with 2-B and 3- degree burn wounds
Status | Recruiting |
Enrollment | 20 |
Est. completion date | December 26, 2018 |
Est. primary completion date | December 26, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Male and female aged 18-65 years; - Patients with 2-nd B and 3-d degree burn wound; - Body surface area involved in burns - from 10 to 50%; - The area of skin grafting - less than 6% of the skin surface; - Burn occurring within the 24 hours prior to the hospitalization; - Adequate antishock therapy in the prehospital phase; - Women of childbearing age to provide proof of a current, valid negative pregnancy test; - Confirmation of participation in the study by signing the Instrument of Consent, personally or through a responsible caretaker. Exclusion Criteria: - Prognostically favorable or unfavorable outcome of the disease - (Lesion Severity Index, less than 30 or more, than 120 score); - Combined trauma; - Severe respiratory tract burn injuries; - Ischemic disease of the lower extremities; - The presence of cardiovascular disease (CVD): symptoms of unstable angina, myocarditis, heart disease, heart failure; - History of prior cancer; - Healing of duodenal or gastric ulcers in history; - Diabetes - Severe chronic liver diseases or kidney disease in history; - History of alcohol or other drug abuse; - Pregnan?y; - Any other physical diseases in decompensation or subcompensation, - or those that are rated as severe or moderate; - Therapeutic issues or psychiatric disorders of a patient which would - make the subject unsuitable to participate in this study or to complete it; - Participation in another clinical trial |
Country | Name | City | State |
---|---|---|---|
Ukraine | The Kyiv City Clinical Hospital ?2 | Kyiv |
Lead Sponsor | Collaborator |
---|---|
A.A. Partners, LLC |
Ukraine,
Alexaki VI, Simantiraki D, Panayiotopoulou M, Rasouli O, Venihaki M, Castana O, Alexakis D, Kampa M, Stathopoulos EN, Castanas E. Adipose tissue-derived mesenchymal cells support skin reepithelialization through secretion of KGF-1 and PDGF-BB: comparison with dermal fibroblasts. Cell Transplant. 2012;21(11):2441-54. doi: 10.3727/096368912X637064. Epub 2012 Apr 10. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The degree of healing of skin flap; The degree of epithelialization of burn wounds in the perforations of a skin graft | The degree of healing of skin flap after autologous skin grafting; | up to 1 month | |
Secondary | The dynamics of healing of skin flap | Complete epithelization or epithelization more than 50% of the cells in the skin graft on the 10th day after autologous skin grafting are effective. The epithelialization less than 50% is not effective. | up to 1 month | |
Secondary | Dynamics of the phagocytic activity of neutrophils in the area of burn wounds, according to NBT-test. | Dynamics of the phagocytic activity of neutrophils in the area of burn wounds, according to NBT-test. | up to 1 month | |
Secondary | Duration of treatment (days) to complete epithelialization of burn wounds; | Duration of treatment (days) to complete epithelialization of burn wounds; | up to 1 month |